U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Muscle stiffness

MedGen UID:
113151
Concept ID:
C0221170
Sign or Symptom
Synonym: Stiff muscles
SNOMED CT: Muscle stiffness (16046003); Muscular stiffness (16046003)
 
HPO: HP:0003552

Definition

A condition in which muscles cannot be moved quickly without accompanying pain or spasm. [from HPO]

Term Hierarchy

Conditions with this feature

Paramyotonia congenita of Von Eulenburg
MedGen UID:
113142
Concept ID:
C0221055
Disease or Syndrome
Paramyotonia congenita (PMC) is an autosomal dominant myotonic disorder characterized by cold-induced prolonged localized muscle contraction and weakness. Patients may experience episodes of generalized weakness (periodic paralysis) unassociated with cold exposure (summary by Ptacek et al., 1992).
Congenital myotonia, autosomal recessive form
MedGen UID:
155852
Concept ID:
C0751360
Disease or Syndrome
Myotonia congenita is characterized by muscle stiffness present from childhood; all striated muscle groups including the extrinsic eye muscles, facial muscles, and tongue may be involved. Stiffness is relieved by repeated contractions of the muscle (the "warm-up" phenomenon). Muscles are usually hypertrophic. Whereas autosomal recessive (AR) myotonia congenita is often associated with more severe manifestations (such as progressive minor distal weakness and attacks of transient weakness brought on by movement after rest), autosomal dominant (AD) myotonia congenita is not. The age of onset varies: in AD myotonia congenita onset is usually in infancy or early childhood; in AR myotonia congenita the average age of onset is slightly older. In both AR and AD myotonia congenita onset may be as late as the third or fourth decade of life.
TNF receptor-associated periodic fever syndrome (TRAPS)
MedGen UID:
226899
Concept ID:
C1275126
Disease or Syndrome
Familial periodic fever (FPF) is an autoinflammatory disorder characterized by recurrent fever with localized myalgia and painful erythema. Febrile attacks may last 1 or 2 days but often last longer than 1 week. Arthralgia of large joints, abdominal pain, conjunctivitis, and periorbital edema are common features. During attacks, painless cutaneous lesions may develop on the trunk or extremities and may migrate distally (review by Drenth and van der Meer, 2001).
Carnitine palmitoyl transferase II deficiency, myopathic form
MedGen UID:
371584
Concept ID:
C1833508
Disease or Syndrome
Carnitine palmitoyltransferase II (CPT II) deficiency is a disorder of long-chain fatty-acid oxidation. The three clinical presentations are lethal neonatal form, severe infantile hepatocardiomuscular form, and myopathic form (which is usually mild and can manifest from infancy to adulthood). While the former two are severe multisystemic diseases characterized by liver failure with hypoketotic hypoglycemia, cardiomyopathy, seizures, and early death, the latter is characterized by exercise-induced muscle pain and weakness, sometimes associated with myoglobinuria. The myopathic form of CPT II deficiency is the most common disorder of lipid metabolism affecting skeletal muscle and the most frequent cause of hereditary myoglobinuria. Males are more likely to be affected than females.
Nemaline myopathy 6
MedGen UID:
373095
Concept ID:
C1836472
Disease or Syndrome
Nemaline myopathy-6 is an autosomal dominant skeletal muscle disorder characterized by childhood onset of slowly progressive proximal muscle weakness, exercise intolerance, and slow movements with stiff muscles. Patients are unable to run or correct themselves from falling over. Histopathologic changes seen on skeletal muscle biopsy include nemaline rods, cores devoid of oxidative enzyme activity, and predominance of hypertrophic type 1 fibers. There is no cardiac or respiratory involvement (summary by Sambuughin et al., 2010).
Hereditary spastic paraplegia 7
MedGen UID:
339552
Concept ID:
C1846564
Disease or Syndrome
Spastic paraplegia 7 (SPG7) is characterized by insidiously progressive bilateral leg weakness and spasticity. Most affected individuals have decreased vibration sense and cerebellar signs. Onset is mostly in adulthood, although symptoms may start as early as age 11 years and as late as age 72 years. Additional features including ataxia (gait and limbs), spastic dysarthria, dysphagia, pale optic disks, ataxia, nystagmus, strabismus, ptosis, hearing loss, motor and sensory neuropathy, amyotrophy, scoliosis, pes cavus, and urinary sphincter disturbances may be observed.
Congenital generalized lipodystrophy type 4
MedGen UID:
412871
Concept ID:
C2750069
Disease or Syndrome
Congenital generalized lipodystrophy type 4 (CGL4) combines the phenotype of classic Berardinelli-Seip lipodystrophy (608594) with muscular dystrophy and cardiac conduction anomalies (Hayashi et al., 2009). For a general description and a discussion of genetic heterogeneity of congenital generalized lipodystrophy, see CGL1 (608594).
Glycogen storage disease due to lactate dehydrogenase M-subunit deficiency
MedGen UID:
419152
Concept ID:
C2931743
Disease or Syndrome
Lactate dehydrogenase deficiency is a condition that affects how the body breaks down sugar to use as energy in cells, primarily muscle cells.\n\nPeople with lactate dehydrogenase-A deficiency experience fatigue, muscle pain, and cramps during exercise (exercise intolerance). In some people with lactate dehydrogenase-A deficiency, high-intensity exercise or other strenuous activity leads to the breakdown of muscle tissue (rhabdomyolysis). The destruction of muscle tissue releases a protein called myoglobin, which is processed by the kidneys and released in the urine (myoglobinuria). Myoglobin causes the urine to be red or brown. This protein can also damage the kidneys, in some cases leading to life-threatening kidney failure. Some people with lactate dehydrogenase-A deficiency develop skin rashes. The severity of the signs and symptoms among individuals with lactate dehydrogenase-A deficiency varies greatly.\n\nThere are two types of this condition: lactate dehydrogenase-A deficiency (sometimes called glycogen storage disease XI) and lactate dehydrogenase-B deficiency.\n\nPeople with lactate dehydrogenase-B deficiency typically do not have any signs or symptoms of the condition. They do not have difficulty with physical activity or any specific physical features related to the condition. Affected individuals are usually discovered only when routine blood tests reveal reduced lactate dehydrogenase activity.
Potassium-aggravated myotonia
MedGen UID:
444151
Concept ID:
C2931826
Disease or Syndrome
In a report on the 37th ENMC Workshop, Rudel and Lehmann-Horn (1997) stated that the sodium channelopathies can be divided into 3 different forms: paramyotonia, potassium-aggravated myotonia, and periodic paralysis. Potassium-aggravated myotonia includes mild myotonia fluctuans, severe myotonia permanens, and acetazolamide-responsive myotonia.
Congenital myotonia, autosomal dominant form
MedGen UID:
422446
Concept ID:
C2936781
Disease or Syndrome
Myotonia congenita is characterized by muscle stiffness present from childhood; all striated muscle groups including the extrinsic eye muscles, facial muscles, and tongue may be involved. Stiffness is relieved by repeated contractions of the muscle (the "warm-up" phenomenon). Muscles are usually hypertrophic. Whereas autosomal recessive (AR) myotonia congenita is often associated with more severe manifestations (such as progressive minor distal weakness and attacks of transient weakness brought on by movement after rest), autosomal dominant (AD) myotonia congenita is not. The age of onset varies: in AD myotonia congenita onset is usually in infancy or early childhood; in AR myotonia congenita the average age of onset is slightly older. In both AR and AD myotonia congenita onset may be as late as the third or fourth decade of life.
Hyperekplexia 3
MedGen UID:
766202
Concept ID:
C3553288
Disease or Syndrome
Hereditary hyperekplexia may explain some cases of sudden infant death syndrome (SIDS), which is a major cause of unexplained death in babies younger than 1 year.\n\nThe signs and symptoms of hereditary hyperekplexia typically fade by age 1. However, older individuals with hereditary hyperekplexia may still startle easily and have periods of rigidity, which can cause them to fall down. They may also continue to have hypnagogic myoclonus or movements during sleep. As they get older, individuals with this condition may have a low tolerance for crowded places and loud noises. People with hereditary hyperekplexia who have epilepsy have the seizure disorder throughout their lives.\n\nOther signs and symptoms of hereditary hyperekplexia can include muscle twitches when falling asleep (hypnagogic myoclonus) and movements of the arms or legs while asleep. Some infants, when tapped on the nose, extend their head forward and have spasms of the limb and neck muscles. Rarely, infants with hereditary hyperekplexia experience recurrent seizures (epilepsy).\n\nHereditary hyperekplexia is a condition in which affected infants have increased muscle tone (hypertonia) and an exaggerated startle reaction to unexpected stimuli, especially loud noises. Following the startle reaction, infants experience a brief period in which they are very rigid and unable to move. During these rigid periods, some infants stop breathing, which, if prolonged, can be fatal. Infants with hereditary hyperekplexia have hypertonia at all times, except when they are sleeping.
Hyperekplexia 2
MedGen UID:
766205
Concept ID:
C3553291
Disease or Syndrome
Hereditary hyperekplexia is a condition in which affected infants have increased muscle tone (hypertonia) and an exaggerated startle reaction to unexpected stimuli, especially loud noises. Following the startle reaction, infants experience a brief period in which they are very rigid and unable to move. During these rigid periods, some infants stop breathing, which, if prolonged, can be fatal. Infants with hereditary hyperekplexia have hypertonia at all times, except when they are sleeping.\n\nOther signs and symptoms of hereditary hyperekplexia can include muscle twitches when falling asleep (hypnagogic myoclonus) and movements of the arms or legs while asleep. Some infants, when tapped on the nose, extend their head forward and have spasms of the limb and neck muscles. Rarely, infants with hereditary hyperekplexia experience recurrent seizures (epilepsy).\n\nThe signs and symptoms of hereditary hyperekplexia typically fade by age 1. However, older individuals with hereditary hyperekplexia may still startle easily and have periods of rigidity, which can cause them to fall down. They may also continue to have hypnagogic myoclonus or movements during sleep. As they get older, individuals with this condition may have a low tolerance for crowded places and loud noises. People with hereditary hyperekplexia who have epilepsy have the seizure disorder throughout their lives.\n\nHereditary hyperekplexia may explain some cases of sudden infant death syndrome (SIDS), which is a major cause of unexplained death in babies younger than 1 year.
Myofibrillar myopathy 3
MedGen UID:
811509
Concept ID:
C3714934
Disease or Syndrome
Myofibrillar myopathy refers to a genetically heterogeneous group of muscular disorders characterized by a pathologic morphologic pattern of myofibrillar degradation and abnormal accumulation of proteins involved with the sarcomeric Z disc (summary by Foroud et al., 2005). For a general phenotypic description and a discussion of genetic heterogeneity of myofibrillar myopathy, see MFM1 (601419).
Hereditary spastic paraplegia 72
MedGen UID:
816490
Concept ID:
C3810160
Disease or Syndrome
Hereditary spastic paraplegia-72A (SPG72A) is a pure form of spastic paraplegia with onset of difficulty walking and stiff legs associated with hyperreflexia and extensor plantar responses in early childhood. The disorder is slowly progressive, and some patients develop the need for assistance in walking. Some patients may have pes cavus or sphincter disturbances. Cognition, speech, and ocular function are normal (summary by Esteves et al., 2014). For a discussion of genetic heterogeneity of autosomal dominant spastic paraplegia, see SPG3A (182600).
Very long chain acyl-CoA dehydrogenase deficiency
MedGen UID:
854382
Concept ID:
C3887523
Disease or Syndrome
Deficiency of very long-chain acyl-coenzyme A dehydrogenase (VLCAD), which catalyzes the initial step of mitochondrial beta-oxidation of long-chain fatty acids with a chain length of 14 to 20 carbons, is associated with three phenotypes. The severe early-onset cardiac and multiorgan failure form typically presents in the first months of life with hypertrophic or dilated cardiomyopathy, pericardial effusion, and arrhythmias, as well as hypotonia, hepatomegaly, and intermittent hypoglycemia. The hepatic or hypoketotic hypoglycemic form typically presents during early childhood with hypoketotic hypoglycemia and hepatomegaly, but without cardiomyopathy. The later-onset episodic myopathic form presents with intermittent rhabdomyolysis provoked by exercise, muscle cramps and/or pain, and/or exercise intolerance. Hypoglycemia typically is not present at the time of symptoms.
Myopathy, tubular aggregate, 1
MedGen UID:
860163
Concept ID:
C4011726
Disease or Syndrome
Tubular aggregates in muscle, first described by Engel (1964), are structures of variable appearance consisting of an outer tubule containing either one or more microtubule-like structures or amorphous material. They are a nonspecific pathologic finding that may occur in a variety of circumstances, including alcohol- and drug-induced myopathies, exercise-induced cramps or muscle weakness, and inherited myopathies. Tubular aggregates are derived from the sarcoplasmic reticulum (Salviati et al., 1985) and are believed to represent an adaptive mechanism aimed at regulating an increased intracellular level of calcium in order to prevent the muscle fibers from hypercontraction and necrosis (Martin et al., 1997; Muller et al., 2001). Genetic Heterogeneity of Tubular Aggregate Myopathy See also TAM2 (615883), caused by mutation in the ORAI1 gene (610277) on chromosome 12q24.
Schwartz-Jampel syndrome type 1
MedGen UID:
1647990
Concept ID:
C4551479
Disease or Syndrome
Schwartz-Jampel syndrome type 1 (SJS1) is a rare autosomal recessive disorder characterized by muscle stiffness (myotonia) and chondrodysplasia. Affected individuals usually present in childhood with permanent muscle stiffness or bone deformities. Common clinical features include mask-like facies (narrow palpebral fissures, blepharospasm, and pursed lips); permanent muscle stiffness with continuous skeletal muscle activity recorded on electromyography; dwarfism; pectus carinatum; kyphoscoliosis; bowing of long bones; and epiphyseal, metaphyseal, and hip dysplasia. The disorder is slowly progressive but does not appear to alter life span (summary by Stum et al., 2006).
Dystonia 31
MedGen UID:
1794211
Concept ID:
C5562001
Disease or Syndrome
Dystonia-31 (DYT31) is an autosomal recessive progressive neurologic disorder characterized by involuntary muscle twisting movements and postural abnormalities affecting the upper and lower limbs, neck, face, and trunk. Some patients may have orofacial dyskinesia resulting in articulation and swallowing difficulties. The age at onset ranges from childhood to young adulthood. There are usually no additional neurologic symptoms, although late-onset parkinsonism was reported in 1 family (summary by Zech et al., 2022).
Autosomal recessive axonal neuropathy with neuromyotonia
MedGen UID:
1814513
Concept ID:
C5700127
Disease or Syndrome
NMAN is an autosomal recessive neurologic disorder characterized by onset in the first or second decade of a peripheral axonal neuropathy predominantly affecting motor more than sensory nerves. The axonal neuropathy is reminiscent of Charcot-Marie-Tooth disease type 2 (see, e.g., CMT2A1, 118210) and distal hereditary motor neuropathy (see, e.g., HMND1, 182960). Individuals with NMAN also have delayed muscle relaxation and action myotonia associated with neuromyotonic discharges on needle EMG resulting from hyperexcitability of the peripheral nerves (summary by Zimon et al., 2012).
Spastic paraplegia 88, autosomal dominant
MedGen UID:
1824020
Concept ID:
C5774247
Disease or Syndrome
Autosomal dominant spastic paraplegia-88 (SPG88) is characterized by onset of symptoms in the first year of life. Affected individuals show delayed motor development with walking difficulties due to spasticity of the lower limbs. The disorder is slowly progressive, but variable in severity; some patients are unable to ambulate independently. Most patients have a pure form of the disorder, although rare patients have been reported to have additional features, including peripheral neuropathy, speech delay, ADHD, and nonspecific brain imaging abnormalities (Schob et al., 2021, Estiar et al., 2022, De Winter et al., 2022). For a general phenotypic description and a discussion of genetic heterogeneity of autosomal dominant spastic paraplegia, see SPG3A (182600).

Professional guidelines

PubMed

Stunnenberg BC, LoRusso S, Arnold WD, Barohn RJ, Cannon SC, Fontaine B, Griggs RC, Hanna MG, Matthews E, Meola G, Sansone VA, Trivedi JR, van Engelen BGM, Vicart S, Statland JM
Muscle Nerve 2020 Oct;62(4):430-444. Epub 2020 May 27 doi: 10.1002/mus.26887. PMID: 32270509Free PMC Article
Rabiei Z, Solati K, Amini-Khoei H
Pharm Biol 2019 Dec;57(1):355-362. doi: 10.1080/13880209.2019.1618344. PMID: 31141426Free PMC Article
Park J, Park HJ
Toxins (Basel) 2017 Aug 24;9(9) doi: 10.3390/toxins9090260. PMID: 28837075Free PMC Article

Recent clinical studies

Etiology

Hendricks S, Hill H, Hollander SD, Lombard W, Parker R
J Bodyw Mov Ther 2020 Apr;24(2):151-174. Epub 2019 Nov 2 doi: 10.1016/j.jbmt.2019.10.019. PMID: 32507141
Lin WC, Lee CL, Chang NJ
J Sports Sci Med 2020 Jun;19(2):420-428. Epub 2020 May 1 PMID: 32390736Free PMC Article
Park SH, Lee MM
Med Sci Monit 2020 Mar 23;26:e920208. doi: 10.12659/MSM.920208. PMID: 32202262Free PMC Article
Smith MS, Olivas J, Smith K
Am Fam Physician 2019 Feb 15;99(4):248-252. PMID: 30763049
Konrad A, Stafilidis S, Tilp M
Scand J Med Sci Sports 2017 Oct;27(10):1070-1080. Epub 2016 Jul 1 doi: 10.1111/sms.12725. PMID: 27367916Free PMC Article

Diagnosis

Vivekanandam V, Jayaseelan D, Hanna MG
Handb Clin Neurol 2023;195:521-532. doi: 10.1016/B978-0-323-98818-6.00006-6. PMID: 37562884
Dalakas MC
Neurotherapeutics 2022 Apr;19(3):832-847. Epub 2022 Jan 27 doi: 10.1007/s13311-022-01188-w. PMID: 35084720Free PMC Article
Stunnenberg BC, LoRusso S, Arnold WD, Barohn RJ, Cannon SC, Fontaine B, Griggs RC, Hanna MG, Matthews E, Meola G, Sansone VA, Trivedi JR, van Engelen BGM, Vicart S, Statland JM
Muscle Nerve 2020 Oct;62(4):430-444. Epub 2020 May 27 doi: 10.1002/mus.26887. PMID: 32270509Free PMC Article
Lee G
R I Med J (2013) 2014 Nov 3;97(11):22-4. PMID: 25365815
Meinck HM
CNS Drugs 2001;15(7):515-26. doi: 10.2165/00023210-200115070-00002. PMID: 11510622

Therapy

Stunnenberg BC, LoRusso S, Arnold WD, Barohn RJ, Cannon SC, Fontaine B, Griggs RC, Hanna MG, Matthews E, Meola G, Sansone VA, Trivedi JR, van Engelen BGM, Vicart S, Statland JM
Muscle Nerve 2020 Oct;62(4):430-444. Epub 2020 May 27 doi: 10.1002/mus.26887. PMID: 32270509Free PMC Article
Ikeda N, Otsuka S, Kawanishi Y, Kawakami Y
Med Sci Sports Exerc 2019 Oct;51(10):2166-2172. doi: 10.1249/MSS.0000000000002035. PMID: 31083046Free PMC Article
Smith MS, Olivas J, Smith K
Am Fam Physician 2019 Feb 15;99(4):248-252. PMID: 30763049
Freitas SR, Mendes B, Le Sant G, Andrade RJ, Nordez A, Milanovic Z
Scand J Med Sci Sports 2018 Mar;28(3):794-806. Epub 2017 Oct 9 doi: 10.1111/sms.12957. PMID: 28801950
Park J, Park HJ
Toxins (Basel) 2017 Aug 24;9(9) doi: 10.3390/toxins9090260. PMID: 28837075Free PMC Article

Prognosis

Sharma N, Venkadesan M
Proc Natl Acad Sci U S A 2022 Mar 22;119(12):e2122903119. Epub 2022 Mar 16 doi: 10.1073/pnas.2122903119. PMID: 35294291Free PMC Article
Damanti S, Cilla M, Tuscano B, De Lorenzo R, Manganaro G, Merolla A, Pacioni G, Pomaranzi C, Tiraferri V, Martinenghi S, Vitali G, Bosi E, Conte C, Giustina A, Tresoldi M, Rovere Querini P
Front Endocrinol (Lausanne) 2022;13:801133. Epub 2022 Feb 17 doi: 10.3389/fendo.2022.801133. PMID: 35250860Free PMC Article
Albin SR, Koppenhaver SL, Marcus R, Dibble L, Cornwall M, Fritz JM
J Orthop Sports Phys Ther 2019 May;49(5):310-319. Epub 2019 Feb 13 doi: 10.2519/jospt.2019.8864. PMID: 30759357
van Alfen N, Gijsbertse K, de Korte CL
Curr Opin Neurol 2018 Oct;31(5):568-574. doi: 10.1097/WCO.0000000000000589. PMID: 30028736
Lee G
R I Med J (2013) 2014 Nov 3;97(11):22-4. PMID: 25365815

Clinical prediction guides

Rubine-Gatina S, Rimere N, Zundane Z, Gulajeva A, Reste J
IISE Trans Occup Ergon Hum Factors 2022 Oct-Dec;10(4):192-200. Epub 2022 Dec 1 doi: 10.1080/24725838.2022.2141369. PMID: 36308294
Sharma N, Venkadesan M
Proc Natl Acad Sci U S A 2022 Mar 22;119(12):e2122903119. Epub 2022 Mar 16 doi: 10.1073/pnas.2122903119. PMID: 35294291Free PMC Article
Ferreira-Sánchez MDR, Moreno-Verdú M, Cano-de-la-Cuerda R
Sensors (Basel) 2020 Feb 6;20(3) doi: 10.3390/s20030880. PMID: 32041374Free PMC Article
Paige NM, Miake-Lye IM, Booth MS, Beroes JM, Mardian AS, Dougherty P, Branson R, Tang B, Morton SC, Shekelle PG
JAMA 2017 Apr 11;317(14):1451-1460. doi: 10.1001/jama.2017.3086. PMID: 28399251Free PMC Article
Konrad A, Stafilidis S, Tilp M
Scand J Med Sci Sports 2017 Oct;27(10):1070-1080. Epub 2016 Jul 1 doi: 10.1111/sms.12725. PMID: 27367916Free PMC Article

Recent systematic reviews

Takeuchi K, Nakamura M, Konrad A, Mizuno T
Scand J Med Sci Sports 2023 Aug;33(8):1294-1306. Epub 2023 May 25 doi: 10.1111/sms.14402. PMID: 37231582
Hendricks S, Hill H, Hollander SD, Lombard W, Parker R
J Bodyw Mov Ther 2020 Apr;24(2):151-174. Epub 2019 Nov 2 doi: 10.1016/j.jbmt.2019.10.019. PMID: 32507141
Ferreira-Sánchez MDR, Moreno-Verdú M, Cano-de-la-Cuerda R
Sensors (Basel) 2020 Feb 6;20(3) doi: 10.3390/s20030880. PMID: 32041374Free PMC Article
Freitas SR, Mendes B, Le Sant G, Andrade RJ, Nordez A, Milanovic Z
Scand J Med Sci Sports 2018 Mar;28(3):794-806. Epub 2017 Oct 9 doi: 10.1111/sms.12957. PMID: 28801950
Paige NM, Miake-Lye IM, Booth MS, Beroes JM, Mardian AS, Dougherty P, Branson R, Tang B, Morton SC, Shekelle PG
JAMA 2017 Apr 11;317(14):1451-1460. doi: 10.1001/jama.2017.3086. PMID: 28399251Free PMC Article

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Recent activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...